Variables | Experimental group (n) | Control group (n) |
---|---|---|
At randomisation | ||
Birth weight (g) | ||
Gestational age (weeks) | ||
Apgar 1 min (1–10) | ||
Apgar 5 min (1–10) | ||
Gender | ||
Male (%) | ||
Female (%) | ||
At 72 h of age | ||
Age when NIRS monitoring started (h)a | N/A | |
Stopping NIRS monitoring before end of monitoring period (%)a | N/A | |
Parents discontinuing trial participation (%) | ||
Changes in treatment due to cerebral hypoxia (%)a | N/A | |
Registered cardiovascular support treatment (%)a | N/A | |
Type of NIRS device useda INVOS (%) NIRO (%) Fore-Sight (%) Sensmart (%) O3 (%) Egos (%) Oxyprem (%) Other (%) | N/A | |
Cerebral NIRS monitoring despite being in control group (%)b | N/A | |
Surfactant therapy (%) | ||
Severe adverse reactions (%) | ||
At 36 weeks postmenstrual age | ||
Major congenital anomaly (%) | ||
Mechanical ventilation (%) | ||
Time with mechanical ventilation (days) | ||
Patent ductus arteriosus (%) | ||
Weight (g) | ||
Early cranial ultrasound scan (%) | ||
Late cranial ultrasound scan (%) |